CytRx Corporation filed its 10-K on Mar 23, 2022 for the period ending Dec 31, 2021. In this report its auditor, Weinberg & Company, P.A., gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.3 USD | +2.68% | -2.13% | +76.92% |
Jun. 04 | LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License | CI |
May. 15 | LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
+76.92% | 1.14M | |
+17.09% | 44.63B | |
+42.10% | 40.46B | |
-9.70% | 38.07B | |
+33.28% | 32.27B | |
-8.98% | 27.3B | |
+13.37% | 26.53B | |
+44.11% | 14.06B | |
+32.33% | 12.54B | |
-7.26% | 11.28B |
- Stock Market
- Equities
- LADX Stock
- News LadRx Corporation
- CytRx Corporation Auditor Raises 'Going Concern' Doubt